Patent · US Active

Treating sickle cell disease with a pyruvate kinase R activating compound

US11980611B2 · kind B2 · utility

3Cited by

72References

4Claims

0Family size

Assignee

Novo Nordisk Health Care AG · CH

Inventors

Anna Ericsson · Keyano, CA
Neal Green · Newton, US
Gary Gustafson · Ridgefield, US
Bingsong Han · Westwood, US
David R. Lancia, Jr. · Boston, US
Lorna Helen Mitchell · Auckland, NZ
David Richard · Monroe, US
Tatiana Shelekhin · Ridgefield, US
Chase C. Smith · Rutland, US
Zhongguo Wang · Lexington, US
Xiaozhang Zheng · Lexington, US

Key dates

Filing date	Dec 22, 2022
Grant date	May 14, 2024
Priority date	—
Expiry date	Jan 3, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D491/056
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.